Zevra Therapeutics, Inc. ZVRA

ZVRA Company Overview

Zevra Therapeutics, Inc. is a U.S.-based rare disease biotechnology company focused on developing and commercializing therapies for patients with rare metabolic, neurologic, and genetic disorders that have limited or no approved treatment options. The company operates within the biopharmaceutical industry, with strategic emphasis on orphan diseases that may qualify for regulatory incentives such as orphan drug designation, priority review vouchers, and accelerated approval pathways. Its core business model combines internal drug development with acquisition and in-licensing of late-stage or commercial rare disease assets.

The company’s principal revenue drivers are product commercialization activities and milestone-related collaboration arrangements tied to its rare disease portfolio. Zevra has concentrated on therapies addressing conditions such as Niemann-Pick disease type C and other ultra-rare disorders. Historically, the company operated under the name KemPharm, Inc., initially focused on proprietary prodrug technologies for attention-deficit hyperactivity disorder and central nervous system therapeutics. The company later rebranded to Zevra Therapeutics to reflect a strategic transition toward rare disease therapeutics and specialty commercialization.